Trials utilizing CRISPR/Cas9-mediated CCR5 deletion of hematopoietic stem cells in HIV-1 and acute lymphoblastic leukemia patients have been partially successful (NCT03164137), which emphasizes a need for more efficient disruption of CCR5 in lymphocytes (276). The gene discussed is CCR5; the disease is acute lymphoblastic leukemia.